• It is predicted that China Actual NIPT test volume will increase to 1.6 Million by 2024

• More than 3,00,000 NIFTY tests done in 2016

• Berry Genomics completes US$ 648 Million reverse merger in Shenzhen

• Two–Child policy is likely to boost China NIPT market

Growth in China NIPT market can be attributed to factors such as high incidence rate of babies born with Down syndrome, no risk of miscarriage with NIPT and shifting trend towards child bearing at advanced maternal age (35 years or older). High test cost, strict regulatory requirements and ethical hurdles is restraining the growth of China NIPT market. Due to expanding patient access to NIPT test, the China NIPT test market is poised to have a positive outlook in the year ahead.

The report contains a granular analysis of the market segmentation, reveal facts on the market size, volume and revenues; and provides forecasts through 2024. It also includes a snapshot of the NIPT implementation in the low and middle-income countries. The report also explores detailed description of growth drivers and inhibitors of the China NIPT Market.

The report concludes with the profiles of major players in the China NIPT Market. The key market players are evaluated on various parameters such as company introduction, NIPT test portfolio, NIPT test analysis with volume and market revenue and latest development/updates of the NIPT Market in China.